Abstract：
Quinoline-based fibroblast activation protein (FAP) inhibitors (FAPIs) have recently emerged as a focal point in global nuclear medicine, underscored by their promising applications in cancer theranostics and the diagnosis of various nononcological conditions. This review offers an in-depth summary of the existing literature on the evolution and use of FAPI tracers in China, tracing their journey from preclinical to clinical research. Moreover, this review also assesses the diagnostic accuracy of FAPI PET for the most common cancers in China, analyzes its impact on oncologic management paradigms, and investigates the potential of FAP-targeted radionuclide therapy in patients with advanced or metastatic cancer. This review also summarizes studies using FAPI PET for nononcologic disorders in China. Thus, this qualitative overview presents a snapshot of China\'s engagement with FAPI tracers, aiming to guide future research endeavors.
摘要：
基于喹啉的成纤维细胞活化蛋白（FAP）抑制剂（FAPI）最近已成为全球核医学的焦点。强调了它们在癌症治疗和各种非肿瘤疾病的诊断中的有希望的应用。这篇综述对中国现有的FAPI示踪剂的发展和使用进行了深入的总结，追踪他们从临床前到临床研究的旅程。此外，这篇综述还评估了FAPIPET对中国最常见癌症的诊断准确性，分析了它对肿瘤管理范式的影响，并研究了FAP靶向放射性核素治疗在晚期或转移性癌症患者中的潜力。本文还总结了使用FAPIPET治疗中国非肿瘤疾病的研究。因此，这份定性概述提供了中国与FAPI示踪剂接触的快照，旨在指导未来的研究工作。
